Skip to content
Alpha Reels Studio

{‘She has no qualifications’: the American scientific community girds for Tracy Beth Høeg’s appointment at the FDA.

As the US proceeds with unprecedented changes to its vaccination recommendations, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccines in the global health crisis and has concentrated on alleged fatalities following COVID-19 immunization in her short position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Program

Public health authorities were set to reveal sweeping revisions to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US out of step with much of the world with insufficient data for improved outcomes. The planned update has been postponed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to speak at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this year.

A Shift at the FDA

The acting appointment may indicate a strengthened alliance between the drug and vaccine centers as Høeg and Prasad solidify control at the agency – and it points to a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric vaccine recommendations in the US to become more similar to Denmark, a society with universal health coverage and a population about the population of Wisconsin’s.

To date comments, she has continued to focus on vaccines – typically the domain of Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has little discernible track record in drug development, oversight or leadership, which has been customary for previous leaders of the CBER. She has worked at the FDA as a key advisor to the commissioner and CBER since spring.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in leading a sizeable institution. She has no expertise in industry regulation.”

Previous heads of CBER would “understand laws and regulations and the research of pharmaceutical innovation”, said Janet Woodcock. “Clearly, she has not acquired the kind of background that prior appointees who ran the center have had.”

CDER has an enormous range of responsibilities at the FDA, Woodcock emphasized.

“The public just focuses on the new drug program, but the generic program approves a multitude of generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these must be managed,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a major management component to the job, which oversees over 5,000 staff members. “It is a huge management job, if you do it right,” she said.

Response and Disputed Programs

In response to concerns about Høeg’s qualifications and whether this selection represents more teamwork among agency officials on vaccines, a representative said that the “questions rely on incorrect assumptions”.

“Her experience matches the duties of her role,” the spokesperson explained, noting the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg takes over the agency head's controversial priority voucher program, a contentious expedited therapy clearance system that allegedly worried her preceding directors. “By what process are these medications being selected for this fast-track system? Who makes the decisions?” Dr. Howard asked. “There’s a lot of confidentiality happening at the regulatory body right now.”

Overall, he remarked, “the FDA seems to be moving towards laxer oversight of all drugs, with the exception of vaccines.”

Documented Past Work on Immunizations

With immunizations, Høeg has a more established, if concerning, past, some experts said. She released a research paper using non-validated crowd-sourced reports to estimate the rate of heart inflammation following Covid vaccination. She counseled the state of Florida top health official Joseph Ladapo, who was said to have modified findings to indicate Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the new federal leadership encompassed altering rules for recently developed shots and ending “non-essential” immunizations, she stated post-election on a podcast. At the agency, Høeg has reportedly proposed barring teenage boys from receiving Covid vaccinations.

“She’s an thorough true believer who starts off with her conclusions and reverse-engineers to fit the data in a highly disingenuous, untruthful manner,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow dissenters, {like|

Written by

William Miller

Award-winning video producer and director with over 10 years of experience in digital storytelling and brand content creation.

Alpha Reels Studio

Type to search articles.